Close

SpringWorks Therapeutics Inc. (SWTX) Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

Go back to SpringWorks Therapeutics Inc. (SWTX) Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Southwall Technologies, Inc. (NASDAQ: SWTX) Delayed: 44.20 +0.82 (1.89%)
Previous Close $43.38    52 Week High $14.00 
Open $42.59    52 Week Low $1.92 
Day High $45.20    P/E 56.67 
Day Low $41.75    EPS $0.78 
Volume 999,789